eye_2019 - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Aldeyra Therapeutics enrols first patient in Phase III GUARD study

Proliferative vitreoretinopathy is a rare retinal disease that causes severe retinal scarring and blindness. Credit: Kalea Jerielle on Unsplash.